NexgenRx Announces Q1 2016 Results

TORONTO, ONTARIO--(Marketwired - April 26, 2016) - NEXGENRX INC. ("NexgenRx" or the "Corporation") (TSX VENTURE:NXG) announces revenue of $1,411,929 an increase of 17.5% over the same period last year. Gross profit was $1,133,731 up 17.3% producing net quarterly income of $47,843, compared with $4,560 for the same period last year.

"Our focused sales strategy is generating a broader client base for the company and is reducing our economic dependency on key clients. We have analyzed where we add value in the marketplace, looking at where we win and are concentrating on those areas with successful results" stated Ron Loucks, President & CEO.

About NexgenRx

NexgenRx is Canada's only independent full service claims adjudicator with full front end administration capability. These combined capabilities allow NexgenRx to provide complete solutions to plan sponsors that need sophisticated health benefit technology applications, in a cost- effective manner. NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and deliver superior administration and claims processing solutions at a competitive cost. More information and the full financial statements can be found at www.sedar.com

Caution Regarding Forward-Looking Statements - This news release contains certain forward looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward- looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release."